This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Total investment incurred for setting up the new R&D Rs 250 crore
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
The acquisition is based on an enterprise value of Rs. 1,660 crore
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions
The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Effective, holistic, science-backed targeted solutions for symptomatic treatment
Subscribe To Our Newsletter & Stay Updated
